Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD6474 for Malignant Pleural Effusion in NSCLC
NCT00402896Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2006
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vandetanib in malignant pleural effusion (MPE), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2006; status: terminated.
02
Drugs
vandetanib
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT00402896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402896.